Linkage Infrastructure, Equipment And Facilities - Grant ID: LE140100070
Funder
Australian Research Council
Funding Amount
$650,000.00
Summary
An advanced in vivo imaging facility. An advanced in vivo imaging facility: This project will establish an advanced In Vivo Imaging Facility (IVIF) for examining host-microbe interactions and associated immunological processes within the context of the numerous infectious disease models within the University of Melbourne and associated collaborators. The Zeiss LSM 7MP 2-photon imaging system will provide enhanced capacity to directly visualise cellular and molecular events in real time, with gre ....An advanced in vivo imaging facility. An advanced in vivo imaging facility: This project will establish an advanced In Vivo Imaging Facility (IVIF) for examining host-microbe interactions and associated immunological processes within the context of the numerous infectious disease models within the University of Melbourne and associated collaborators. The Zeiss LSM 7MP 2-photon imaging system will provide enhanced capacity to directly visualise cellular and molecular events in real time, with greater sensitivity and in a broader range of tissues and organs. This will provide the opportunity for novel insights into numerous immunological and host-microbe interactions.Read moreRead less
Octapeptin-based Antibiotics Against Multi-drug Resistant Gram-negative Bacteria
Funder
National Health and Medical Research Council
Funding Amount
$767,504.00
Summary
Infectious disease is a leading cause of death, and the emergence of "superbugs" in the community and hospitals is of grave concern. We have resurrected a ‘forgotten’ antibiotic from the 1970s that kills superbugs causing pneumonia, skin and urinary track infections; diseases that cause death and discomfort for thousands of Australians today. We will determine how the original antibiotic works against superbugs, and use this information to design better drugs for the future.
New Antibiotics And Treatment Methods Against Drug-resistant Bacteria
Funder
National Health and Medical Research Council
Funding Amount
$766,468.00
Summary
Infectious disease is a leading cause of death, and the emergence of "superbugs" in the community and hospitals is of grave concern. We are developing new, powerful antibiotics that can kill superbugs using ‘forgotten’ drugs from the 1970s. These will combat bacteria that cause pneumonia, skin and urinary track infections; diseases that cause death and discomfort for thousands of Australians today. We will also develop methods to directly remove bacteria from blood infections.
How Do Glycosaminoglycans Promote The Propagation Of Prions?
Funder
National Health and Medical Research Council
Funding Amount
$512,270.00
Summary
The prion diseases are a group of transmissible, neurodegenerative disorders affecting both humans and animals. The most common form in humans is sporadic Creutzfeldt-Jakob disease (CJD), although acquired (variant CJD) and inherited (familial CJD) forms are recognised. Prion diseases are transmissible to the same species by inoculation with, or dietary exposure to, infected tissues. The infectious agent, referred to as a prion , has not been identified at the molecular level. However, a major c ....The prion diseases are a group of transmissible, neurodegenerative disorders affecting both humans and animals. The most common form in humans is sporadic Creutzfeldt-Jakob disease (CJD), although acquired (variant CJD) and inherited (familial CJD) forms are recognised. Prion diseases are transmissible to the same species by inoculation with, or dietary exposure to, infected tissues. The infectious agent, referred to as a prion , has not been identified at the molecular level. However, a major component of purified prions is an abnormal disease associated form of the host encoded prion protein. Understanding how the disease associated form of the prion protein is generated and how host-derived cofactors contribute to its formation will help in our understanding of the infectious nature of these diseases and in the development of effective therapeutic and prophylactic strategies. Glycosaminoglycans are host-derived components of the extracellular matrix that are associated with prion protein plaques found in the brain tissue of patients with prion diseases. Glycosaminoglycans are believed to influence the transmission of prions and the ongoing propagation of infectivity. In this study the importance of glycosaminoglycans in the formation of the disease associated prion protein and the generation of infectivity will be investigated using both cell-free and cell-based models of prion propagation. The understanding gained from this study will be used to develop a high throughput assay that can be used to detect prion infection prior to the development of clinical disease and within a time frame whereby therapeutic intervention may be effective.Read moreRead less
Vancomycin Derivatives Active Against Resistant Bacterial Nosocomial Infections
Funder
National Health and Medical Research Council
Funding Amount
$760,763.00
Summary
Bacterial infection is a leading cause of death worldwide and the emergence of superbugs that are resistant to multiple treatments is becoming a major global concern. Vancomycin is the drug of last resort for the treatment of hospital-acquired Gram -positive bacterial infections. We will synthetically modify vancomycin by incorporating naturally occurring membrane-associative peptides to produce novel antibiotics with multiple modes of action to avoid existing bacterial resistance mechanisms.
Targeting Host Pathogen Interactions And Signalling Networks To Promote Death Of Infected Cells And Facilitate Pathogen Clearance
Funder
National Health and Medical Research Council
Summary
Preclinical models of infectious diseases including hepatitis B, HIV, tuberculosis and human herpes virus infections will be used to understand how pathogens interact with host cells. With this understanding we aim to identify which host cell signalling pathways play a critical role in limiting or faciliating pathogen persistence. After identifying the important cellular pathways we aim to target these host cell signalling components with clinical stage drugs to promote pathogen clearance.
Development Of Novel Hybrid Antibiotics For The Treatment Of Hospital And Community Acquired Drug Resistant Gram-Negative And Gram-Postitive Bacterial Infections
Funder
National Health and Medical Research Council
Funding Amount
$715,076.00
Summary
Drug resistant bacteria now pose a serious and growing threat to human health. Many bacteria have developed new resistance mechanisms such that most common antibiotics no longer can protect patients from serious, life-threatening infection. We will modify two existing antibiotics, colistin and carbapenem (a penicillin), to convert it into a more powerful antibiotic that targets resistant bacteria.
Centre For Research Excellence In Critical Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$2,623,406.00
Summary
Severe infection kills millions of people every year, but clinicians and policy makers rarely get the information they need in time to make potentially life-saving decisions about infection. We will apply modern genomics and information systems to better understand infection threats in critical care environments and explore the ethical and medicolegal aspects that may either facilitate or present barriers to important research and time-critical decision making.
Troublesome ticks: a new molecular toolkit to investigate zoonotic tick-borne pathogens in Australia. This project will use the latest molecular diagnostic techniques to address unanswered questions about potential tick-transmitted diseases of humans and companion animals in Australia. The study will identify 'hot-spots' for tick-borne pathogens, identify areas of potential risk for humans, and investigate vector-host-pathogen interactions nationwide.
Ecology and transmission of tick-borne disease in Australia. Ecology and transmission of tick-borne disease in Australia. This project aims to determine the bacterial, protozoal and viral biodiversity in wildlife ticks and their native mammal hosts, and provide new information about the biology and transmission dynamics of these microorganisms and their potential to cause disease in wildlife, domesticated animals and humans. Anticipated outcomes are improved diagnostic tests and management proto ....Ecology and transmission of tick-borne disease in Australia. Ecology and transmission of tick-borne disease in Australia. This project aims to determine the bacterial, protozoal and viral biodiversity in wildlife ticks and their native mammal hosts, and provide new information about the biology and transmission dynamics of these microorganisms and their potential to cause disease in wildlife, domesticated animals and humans. Anticipated outcomes are improved diagnostic tests and management protocols for tick-borne disease in Australia.Read moreRead less